常见问题

What is Fidanacogene Elaparvovec used for?

A gene therapy used to treat adults with moderately severe to severe hemophilia B (a hereditary bleeding disorder). It works by delivering a functional copy of the gene needed to produce clotting factor IX, potentially providing long-term bleeding control after a single treatment.

How does Fidanacogene Elaparvovec work?

Delivers functional copies of a gene to target cells using a viral vector, restoring expression of the deficient protein and correcting the underlying genetic defect.

Is Fidanacogene Elaparvovec an approved drug?

Yes, Fidanacogene Elaparvovec is an approved drug. It has reached clinical phase 4. It is classified as a Gene.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

• ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3990034. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.